The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Pharmacology and Surgery. As part of his studies on Internal medicine, he often connects relevant subjects like Gastroenterology. The study incorporates disciplines such as Clinical endpoint, Clinical trial, Metastatic breast cancer, Placebo and Metastasis in addition to Oncology.
His Trastuzumab study in the realm of Cancer connects with subjects such as Fibroblast growth factor receptor 1. Howard A. Burris has included themes like Protein kinase B and Phosphatidylinositol in his Pharmacology study. His Surgery research focuses on Carcinoma and how it connects with Paclitaxel.
His primary areas of study are Internal medicine, Oncology, Pharmacology, Pharmacokinetics and Cancer. His Internal medicine research incorporates themes from Gastroenterology and Surgery. His Surgery research is multidisciplinary, relying on both Lung cancer and Carcinoma.
Taxane is closely connected to Trastuzumab in his research, which is encompassed under the umbrella topic of Oncology. His Pharmacokinetics research is multidisciplinary, incorporating elements of Rash and Dosing. His Cancer study integrates concerns from other disciplines, such as Placebo, Gynecology and Clinical trial, Pathology.
His scientific interests lie mostly in Internal medicine, Oncology, In patient, Cancer and Cancer research. Internal medicine is often connected to Gastroenterology in his work. The Gastroenterology study which covers Toxicity that intersects with Metastatic Urothelial Carcinoma.
The concepts of his Oncology study are interwoven with issues in Clinical endpoint, Clinical trial, Carboplatin, Metastatic breast cancer and Placebo. His Cancer study also includes
Howard A. Burris focuses on Internal medicine, Oncology, Cancer, Adverse effect and Cancer research. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. The Oncology study combines topics in areas such as Multicenter study, Pertuzumab, Metastatic breast cancer, Placebo and Clinical endpoint.
His biological study spans a wide range of topics, including Immunohistochemistry and Antibody. His Adverse effect research includes themes of Carcinoma, Progression-free survival and Evaluable Disease. His study in the fields of Glioma under the domain of Cancer research overlaps with other disciplines such as In patient and Isocitrate dehydrogenase.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden.
The Lancet (2016)
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga;Mario Campone;Martine Piccart;Howard A. Burris.
The New England Journal of Medicine (2012)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh.
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt.
The New England Journal of Medicine (2005)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap.
The New England Journal of Medicine (2016)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Shirin Khambata-Ford;Christopher R. Garrett;Neal J. Meropol;Mark Basik.
Journal of Clinical Oncology (2007)
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer.
Journal of Clinical Oncology (2008)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett.
The Lancet (2017)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel.
Journal of Clinical Oncology (2011)
Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge.
Journal of Clinical Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: